Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soo Yoon

Showing results (1001-1010 of 1,104) with videos related to

Pageof 111
Sort By:
Cancer Genetics and Cytogenetics|October 20, 2009
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation studyMiyoung Kim, Seon-Hee Yim, Nam-Sun Cho, et al.
Scientific Reports|January 1, 2020
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysisJung Yong Hong, Dok Hyun Yoon, Sang Eun Yoon, et al.
Leukemia Research|December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
Blood Cancer Journal|October 10, 2019
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma NetworkCinnie Yentia Soekojo, Kihyun Kim, Shang-Yi Huang, et al.
Brain Research|July 3, 2007
Human glycine alpha1 receptor inhibition by quercetin is abolished or inversed by alpha267 mutations in transmembrane domain 2Byung-Hwan Lee, Jun-Ho Lee, In-Soo Yoon, et al.
Transplantation and Cellular Therapy|December 16, 2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage ChemotherapyAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridizationYoungil Koh, Dae-Young Kim, Sung-Hyo Park, et al.
The Lancet. Haematology|October 19, 2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
British Journal of Haematology|January 21, 2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trialJin Lu, Jae H Lee, Shang-Yi Huang, et al.
Pediatric Transplantation|February 2, 2010
The outcome of hematopoietic stem cell transplantation in Korean children with hemophagocytic lymphohistiocytosisHoi Soo Yoon, Ho Joon Im, Hyung Nam Moon, et al.
Pageof 111

Showing results (1001-1010 of 1,104) with videos related to

Sort By:
Pageof 111
Cancer Genetics and Cytogenetics|October 20, 2009
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation studyMiyoung Kim, Seon-Hee Yim, Nam-Sun Cho, et al.
Scientific Reports|January 1, 2020
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysisJung Yong Hong, Dok Hyun Yoon, Sang Eun Yoon, et al.
Leukemia Research|December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
Blood Cancer Journal|October 10, 2019
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma NetworkCinnie Yentia Soekojo, Kihyun Kim, Shang-Yi Huang, et al.
Brain Research|July 3, 2007
Human glycine alpha1 receptor inhibition by quercetin is abolished or inversed by alpha267 mutations in transmembrane domain 2Byung-Hwan Lee, Jun-Ho Lee, In-Soo Yoon, et al.
Transplantation and Cellular Therapy|December 16, 2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage ChemotherapyAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridizationYoungil Koh, Dae-Young Kim, Sung-Hyo Park, et al.
The Lancet. Haematology|October 19, 2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
British Journal of Haematology|January 21, 2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trialJin Lu, Jae H Lee, Shang-Yi Huang, et al.
Pediatric Transplantation|February 2, 2010
The outcome of hematopoietic stem cell transplantation in Korean children with hemophagocytic lymphohistiocytosisHoi Soo Yoon, Ho Joon Im, Hyung Nam Moon, et al.
Pageof 111